Jagsonpal Pharmaceuticals Ltd: Hormones, Headlines & High Margins—Is Jagsonpal the Gynecologist’s Best Friend?
1. At a Glance
Jagsonpal Pharmaceuticals is a ₹1,680 Cr midcap player dominating India’s gynecology and orthopaedics pharma market with margin-rich products, a 900+ strong sales force, and now—USFDA drama, a ₹41 Cr asset sale, and one fat 125% dividend.
2. Introduction with Hook
Imagine a soap opera set in a pharmacy—there’s a CEO making strategic acquisitions, the CFO dramatically exits, the USFDA throws a plot twist, and somewhere between all this, profit doubles. Welcome to Jagsonpal Pharma: the drama queen of healthcare smallcaps.
FY25 Revenue: ₹269 Cr (+28.8%)
FY25 PAT: ₹55 Cr (+150%)
Dividends: 125% payout—more generous than your NRI uncle in December
3. Business Model (WTF Do They Even Do?)
Jagsonpal makes and sells essential medicines primarily for:
Gynecology: 47% of revenue from top 5 brands
Orthopaedics
OTC, Dermatology, Pediatrics, Immunity
It owns 17 top-5 brands in their respective molecule categories, maintains a 900+ strong sales army, and has been busy buying out Yash Pharma and Resilient Cosmeceuticals to diversify and grow.
It’s basically the Durex of hormone therapies. Only with more margin and less awkwardness.
